Analysts at KeyCorp began coverage on shares of Astrana Health (NASDAQ:ASTH – Get Free Report) in a note issued to investors on Friday, Marketbeat reports. The brokerage set a “sector weight” rating on the stock.
Other equities analysts have also recently issued reports about the company. Robert W. Baird increased their target price on Astrana Health from $54.00 to $67.00 and gave the stock an “outperform” rating in a report on Thursday, August 15th. Stifel Nicolaus increased their price objective on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. BTIG Research boosted their target price on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Finally, Truist Financial increased their target price on shares of Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $61.20.
Get Our Latest Stock Report on ASTH
Astrana Health Stock Performance
Astrana Health (NASDAQ:ASTH – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.01. The company had revenue of $486.30 million during the quarter, compared to analysts’ expectations of $440.68 million. Astrana Health had a net margin of 4.30% and a return on equity of 10.71%. The business’s revenue was up 39.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.28 EPS. Sell-side analysts expect that Astrana Health will post 1.33 EPS for the current year.
Institutional Investors Weigh In On Astrana Health
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC acquired a new position in shares of Astrana Health during the third quarter worth approximately $34,000. Handelsbanken Fonder AB bought a new position in Astrana Health in the 3rd quarter worth approximately $492,000. Granite Bay Wealth Management LLC acquired a new position in Astrana Health during the 3rd quarter worth $290,000. SG Americas Securities LLC acquired a new position in Astrana Health during the 3rd quarter worth $680,000. Finally, Central Pacific Bank Trust Division bought a new position in Astrana Health in the 3rd quarter valued at $160,000. Institutional investors and hedge funds own 52.77% of the company’s stock.
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Further Reading
- Five stocks we like better than Astrana Health
- Differences Between Momentum Investing and Long Term Investing
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What Investors Need to Know About Upcoming IPOs
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.